The Canadian Agency for Drugs and Technologies in Health (CADTH) has launched the CADTH Pharmaceutical Reviews Update. This is a new consolidated publication that will communicate updates to CADTH’s drug review process. It replaces previous individual publications, including CDR Update, pCODR Update, Therapeutic Review Update, and Updates for Patient Groups. In this first issue of the CADTH Pharmaceutical Reviews Update, among other announcements, CADTH invites stakeholder comments on a number of proposals, and announces changes to the Pan-Canadian Oncology Drug Review.
Related Publications & Articles
-
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More -
Ministerial Reliance Order permitting Health Canada to rely on decisions of foreign regulators now in force
On July 15, 2026, the Minister of Health’s Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs ("Reliance Order”) was pub...Read More -
Health Canada seeks feedback on pilot to prioritize domestically manufactured generic drug submissions
In a News Release dated July 15, 2026, Health Canada advised that it is modernizing its regulatory processes to improve efficiency while maintaining high standards for safety, efficacy and quality.Read More
